Everest Medicines Limited
Everest Medicines Limited, a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in China (CN) and operates across key regions in Asia. Founded in 2017, the company has rapidly established itself as a leader in developing innovative therapies for unmet medical needs, particularly in oncology and autoimmune diseases.
With a focus on advanced biopharmaceuticals, Everest Medicines offers a unique portfolio of products that includes novel treatments and therapies designed to improve patient outcomes. The company’s commitment to research and development has led to significant milestones, including strategic partnerships and successful clinical trials. Recognised for its robust pipeline and market position, Everest Medicines continues to make strides in the pharmaceutical landscape, aiming to enhance healthcare accessibility and efficacy across its operational territories.
-14 vs industry average
Everest Medicines Limited’s score of 24 is lower than 38% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Everest Medicines Limited?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Everest Medicines Limited's reported carbon emissions
Everest Medicines Limited, a pharmaceutical preparation manufacturing company based in China, reported total carbon emissions of approximately 4.93 million kg CO2e for the year 2024. This figure encompasses Scope 1, 2, and 3 emissions. For the reporting year 2022, the company's total emissions were approximately 57.46 million kg CO2e. This included Scope 1 emissions of 0 kg CO2e and Scope 2 market-based emissions totalling approximately 1.79 million kg CO2e, primarily from purchased electricity. Everest Medicines Limited has established a five-year target to reduce its emission intensity, measured in tCO2e per employee, by 5% by 2030. This target uses 2024 intensity levels as a baseline and applies to both Scope 1 and Scope 2 emissions. The company also reported an intensity metric of approximately 7,410 kg CO2e per employee, as of the 2024 reporting year.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Everest Medicines Limited’s Climate Goals (2030 & 2050)
2 goals2030
5% reduction in Scope 1
The Group has set a five-year target to reduce emission intensity (tCO2e per employee) by 5% by 2030, using the intensity levels of 2024 as…
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Everest Medicines Limited
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project